NCT00153569
Unknown
Phase 2
Phase II Study of Multiepitope Peptide Vaccination in Combination With Adjuvants GM-CSF and KLH in Metastatic Melanoma
ConditionsMetastatic Melanoma
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Metastatic Melanoma
- Sponsor
- Charite University, Berlin, Germany
- Enrollment
- 25
- Locations
- 1
- Primary Endpoint
- Clinical efficacy
- Last Updated
- 15 years ago
Overview
Brief Summary
This trial assesses the clinical efficacy of a multiepitope peptide vaccine with GM-CSF and KLH as immunological adjuvants in stage IV melanoma patients
Investigators
Eligibility Criteria
Inclusion Criteria
- •Metastatic melanoma
- •HLA-A1, -A2, -A24, -B44
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Clinical efficacy
Secondary Outcomes
- Immune response
- Safety
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
Safety Study of Multiple Peptide Vaccine to Esophageal CancerEsophageal CancerNCT00561275Japanese Foundation for Cancer Research6
Terminated
Phase 1
Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous MelanomaMalignant MelanomaNCT00145158Ludwig Institute for Cancer Research23
Completed
Phase 1
Study of Cancer Peptides Vaccine Plus GM-CSF as Adjuvant Treatment for High Risk (TXN2-3M0) or Metastatic Breast Cancer With No Evidence of DiseaseBreast CancerNCT00674791Duke University13
Unknown
Phase 2
Peptide Vaccination in Treating Patients With Esophageal Cancer (STF-II)Esophageal CancerNCT01267578University of Yamanashi60
Unknown
Phase 2
A Study With Peptide Vaccination in Treating Patients With Esophageal CancerEsophageal CancerNCT00995358University of Yamanashi60